KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Inventory (2018 - 2025)

Rigel Pharmaceuticals has reported Change in Inventory over the past 8 years, most recently at -$1.1 million for Q4 2025.

  • Quarterly results put Change in Inventory at -$1.1 million for Q4 2025, up 41.25% from a year ago — trailing twelve months through Dec 2025 was $5.6 million (up 837.57% YoY), and the annual figure for FY2025 was $5.6 million, up 837.57%.
  • Change in Inventory for Q4 2025 was -$1.1 million at Rigel Pharmaceuticals, down from -$188000.0 in the prior quarter.
  • Over the last five years, Change in Inventory for RIGL hit a ceiling of $8.4 million in Q2 2025 and a floor of -$3.3 million in Q3 2024.
  • Median Change in Inventory over the past 5 years was -$151000.0 (2021), compared with a mean of $547550.0.
  • Biggest five-year swings in Change in Inventory: skyrocketed 2078.51% in 2021 and later crashed 1090.04% in 2024.
  • Rigel Pharmaceuticals' Change in Inventory stood at -$450000.0 in 2021, then surged by 540.67% to $2.0 million in 2022, then crashed by 227.63% to -$2.5 million in 2023, then grew by 23.94% to -$1.9 million in 2024, then soared by 41.25% to -$1.1 million in 2025.
  • The last three reported values for Change in Inventory were -$1.1 million (Q4 2025), -$188000.0 (Q3 2025), and $8.4 million (Q2 2025) per Business Quant data.